Regeneron

ClinicalJuly 30, 2026

Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy

Regeneron Pharmaceuticals is conducting a proof-of-concept study to evaluate linvoseltamab's efficacy in eliminating abnormal plasma cells in patients at risk of multiple myeloma.

Recent signals(13)

FDA Accepts Supplement for LYNOZYFIC (BLA761400) from Regeneron

Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy

FDA grants supplemental application approval for Dupixent (BLA761055)

Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC

Regeneron initiates dose escalation study of bispecific antibodies for Lupus Nephritis

FDA Accepts Supplemental Application for Dupixent (Dupilumab)

Regeneron initiates trial for pozelimab + cemdisiran in PNH patients unresponsive to C5 inhibitors

Regeneron initiates study of REGN13335 for Pulmonary Arterial Hypertension

Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

Upcoming catalysts(1)

Regeneron — Dupixent

Regulatory activity(3)

FDA Accepts Supplement for LYNOZYFIC (BLA761400) from Regeneron

FDA grants supplemental application approval for Dupixent (BLA761055)

FDA Accepts Supplemental Application for Dupixent (Dupilumab)

Clinical activity(9)

Regeneron initiates study on linvoseltamab for high-risk monoclonal gammopathy

Regeneron initiates trial for ubamatamab and REGN7075 in advanced NSCLC

Regeneron initiates dose escalation study of bispecific antibodies for Lupus Nephritis

Regeneron initiates study of REGN13335 for Pulmonary Arterial Hypertension

Phase III Trial of Cemiplimab in NSCLC Post-Surgery Shows Promise for Disease-Free Survival

Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

Phase III Trial Evaluates Cemiplimab with Surgery for Advanced Skin Cancer

CMP-001 and Nivolumab Show Promise in Advanced Melanoma Phase 2/3 Trial

Competitive activity(1)

Regeneron initiates trial for pozelimab + cemdisiran in PNH patients unresponsive to C5 inhibitors

Assets

Therapeutic areas

Indications

Get signals before the market moves